Adapting versatile
polymers to improve
surgical outcomes
and patient recovery

Press Releases

07 November 2014

Polyganics announces divestment of its ENT activities

Groningen, the Netherlands, 7 November 2014 – Polyganics today announces it has signed an agreement to sell its activities in the field of Ear, Nose and Throat (ENT) surgery to Stryker. The ENT activities comprise a portfolio of sinunasal and otological dressings, including the marketed products NASOPORE®, HEMOPORE®, OTOPORE® and NASOPORE-FD®. As part of the agreement, Polyganics will continue to manufacture these products in the coming years.

This is a very important step in our strategy to focus on the successful medical device development based on our proprietary synthetic polymer platforms,” says Rudy Mareel, CEO of Polyganics. “We strongly believe Stryker is the best partner to maximize the commercial potential of our ENT portfolio.

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com